Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab in the phase II ...

Analysis of niraparib-induced changes in glucose levels during three-month therapy in normoglycemic patients with ovarian cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard ...

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...

In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among ...

BRCA1 and BRCA2 are perhaps two of the most famous cancer genes known to science. Their discovery, more than 20 years ago, explained why some breast and ovarian cancers run in families. They hit the ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

AstraZeneca and Merck announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline ...

The landscape of ovarian cancer treatment is evolving, driven by the growing role of genetic markers and personalized medicine, informs Dr. Vamsi Veeramachaneni, chief scientific officer at Strand ...